The worldwide use of artemisinin-based combination therapies (ACTs) has contributed in
recent years to a substantial reduction in deaths resulting from Plasmodium falciparum …

Plasmodium falciparum malaria, an infectious disease caused by a parasitic protozoan,
claims the lives of nearly a million children each year in Africa alone and is a top public …

Evolving resistance to artemisinin-based compounds threatens to derail attempts to control
malaria. Resistance has been confirmed in western Cambodia and has recently emerged in …

Recrudescent infections with the human malaria parasite, Plasmodium falciparum,
presented traditionally the major setback of artemisinin-based monotherapies. Although the …

Due to their remarkable parasitocidal activity, artemisinins represent the key components of
first-line therapies against Plasmodium falciparum malaria. However, the decline in efficacy …

The declining efficacy of artemisinin derivatives against Plasmodium falciparum in western
Cambodia is a major concern. The knowledge gap in the understanding of the mechanisms …

Antimicrobial treatment failure threatens our ability to control infections. In addition to
antimicrobial resistance, treatment failures are increasingly understood to derive from cells …

Reports of emerging resistance to first-line artemisinin antimalarials make it critical to define
resistance mechanisms and identify in vitro correlates of resistance. Here we combine …

Artemisinin and its derivatives (ARTs) are frontline antimalarial drugs. However, ART
monotherapy is associated with a high frequency of recrudescent infection, resulting in …

Controlling the spread of antimalarial drug resistance, especially resistance of P lasmodium
falciparum to artemisinin‐based combination therapies, is a high priority. Available data …